mTOR as a Target for Cancer Therapy
2004; Springer Science+Business Media; Linguagem: Inglês
10.1007/978-3-642-18930-2_20
ISSN2196-9965
AutoresPeter J. Houghton, Shile Huang,
Tópico(s)Protein Degradation and Inhibitors
ResumoThe target of rapamycin, mTOR, acts as a sensor for mitogenic stimuli, such as insulin-like growth factors and cellular nutritional status, regulating cellular growth and division. As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular targeted treatment. Further, a rationale for anticipating tumor-selective activity based on transforming events frequently identified in malignant disease is becoming established.
Referência(s)